A fraction of chronic lymphocytic leukaemia (CLL) cases carry highly homologous B-cell receptors (BCR), i.e. characterized by non-random combinations of immunoglobulin heavy-chain variable (IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3), often associated with a restricted selection of IGVK/L light chains. Such 'stereotyped' BCR occur more frequently in CLL with unmutated (UM) than mutated (M) IGHV genes. We analysed 1426 IG rearrangements (from 1398 CLL cases) by a clustering driven by HCDR3 similarities. Molecular findings were correlated to time-to-treatment (TTT) and presence of known prognosticators. Sixty-nine clusters (319 IG-rearrangements, 22AE4%) with stereotyped BCR were identified. Among 30 confirmed clusters ( ‡3 IG-rearrangements/cluster), we found 14 novel clusters, of which 11 had M IG rearrangements (M clusters) and predominantly (8/11) used IGHV3 subgroup genes. Recurrent cluster-biased amino acid changes were found throughout IGHV sequences of these 'M clusters'. Regarding clinical outcome: (i) UM CLL from the IGHV1-2/1-3/1-18/1-46/7-4-1/IGKV1-39 cluster had poorer prognosis than UM/M cases, or UM cases using the same IGHV genes but not in clusters; (ii) M CLL from the IGHV3-21/IGLV3-21 cluster had TTT similar to UM CLL, and shorter than M CLL expressing IGHV3-21 but not in cluster. Altogether, our analysis identified additional molecular and clinical features for CLL expressing stereotyped BCR.
Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease whose clinical course can be partly foreseen by the presence of mutated (M) or unmutated (UM) immunoglobulin variable (IGV) genes (Shanafelt et al, 2004) . Analysis of immunoglobulin heavy-chain variable (IGHV) gene usage reveals a biased IGHV repertoire in CLL versus normal B cells, and in UM versus M CLL (Chiorazzi & Ferrarini, 2003; Chiorazzi et al, 2005; Fais et al, 1998; Ghia et al, 2005; Hamblin et al, 1999; Johnson et al, 1997; Messmer et al, 2004a; Murray et al, 2008; Rosenquist et al, 1999; Stamatopoulos et al, 2005 Stamatopoulos et al, , 2007 Stevenson & Caligaris-Cappio, 2004; Tobin et al, 2004a) . A significant fraction of CLL carries highly homologous B cell receptors (BCR) characterized by nonrandom stereotyped combinations of specific IGHV genes and heavy-chain complementarity determining region-3 (HCDR3), often associated with a restricted selection of IGV kappa or lambda (IGKV/IGLV) light chains (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2002 Tobin et al, , 2003 Widhopf et al, 2008 Widhopf et al, , 2004 . These observations coupled to an IGHV mutation profile, often consistent with antigen-driven selection (Degan et al, 2004a; Messmer et al, 2004b; Murray et al, 2008) , led to the speculation that CLL pathogenesis may involve specific, though yet unidentified (auto) antigens .
Expression of stereotyped BCR occurs more frequently in UM than in M CLL (Capello et al, 2006; Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004b) . Several UM CLL subsets express stereotyped BCR characterized by usage of IGHV1-69 and a restricted spectrum of IG light chains. Another subset of UM CLL expressing stereotyped BCR is characterized by usage of IGHV1 subgroup genes other than IGHV1-69 coupled to IGKV1-39 light chain (Tobin et al, 2004a; Stamatopoulos et al, 2007; Messmer et al, 2004b) . A non-stochastic pairing of IGHV4-39 and IGKV1-39 usually occurs in IGG-expressing UM CLL (Ghiotto et al, 2004; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a) . Whether stereotyped BCR affects prognosis among UM CLL is still a matter of debate (Panovska-Stavridis et al, 2007; Stamatopoulos et al, 2007) .
Among CLL, skewed usage of IGHV3-21 occurs more frequently in Northern Europe than in Mediterranean or nonEuropean countries (Bomben et al, 2007; Ghia et al, 2008 Ghia et al, , 2005 Thorselius et al, 2006; Tobin et al, 2002 Tobin et al, , 2003 . Although IGHV3-21 CLL often display M IGHV genes, survival is comparable to UM CLL patients (Tobin et al, 2002 (Tobin et al, , 2003 (Tobin et al, , 2004a Thorselius et al, 2006; Bomben et al, 2007) . Many IGHV3-21 CLL display unusually short and highly homologous HCDR3 consistently associated with IGLV3-21 (Bomben et al, 2007; Ghia et al, 2008 Ghia et al, , 2005 Thorselius et al, 2006; Tobin et al, 2004b) . The prognostic relevance of stereotyped BCR among IGHV3-21 CLL remains unclear (Bomben et al, 2007; Ghia et al, 2005; Thorselius et al, 2006) . In addition to IGHV3-21, few other CLL clusters with stereotyped M IG rearrangements have been identified so far (Capello et al, 2004; Murray et al, 2008; Stamatopoulos et al, 2007) .
We investigated BCR rearrangements from a wide series of CLL consecutively enroled by different Italian reference centres (1398 patients accounting for 1426 IG rearrangements). Molecular findings were correlated with disease progression and status of widely used prognosticators. Several novel clusters were identified, mainly represented by M IG rearrangements, and frequently involving IGHV3 subgroup genes. From a clinical standpoint, we refined prognostication of the largest CLL clusters with stereotyped BCR.
Materials and methods

Patients
The study included peripheral blood samples from 1398 unselected CLL (median age: 64AE0 years, range 32-97) collected from the archives of the Clinical and Experimental OncoHaematology Unit, Aviano National Cancer Institute (n = 184); Division of Haematology, Amedeo Avogadro University of Eastern Piedmont, Novara (n = 426); Department of Oncology & Haematology, University of ModenaReggio Emilia (n = 260); S. Eugenio Hospital, University of Tor Vergata, Rome (n = 198); Haematology Unit, University of Siena (n = 155); Haematology Institute, Catholic University, Rome (n = 130); and Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland (n = 45). All patients provided informed consent in accordance with local Institutional Review Board requirements and the Declaration of Helsinki.
Analysis of IGHV, IGKV and IGLV rearrangements and HCDR3-driven clustering
Immunoglobulin heavy-chain variable diversity (D)-joining (J), IGKV-J and IGLV-J rearrangements were amplified from either reverse-transcribed total RNA or genomic DNA (Capello et al, 2004; Degan et al, 2004b; Marasca et al, 2001) . Purified amplicons were sequenced either directly or upon subcloning (Capello et al, 2004; Degan et al, 2004b) . Sequences were aligned to the ImMunoGeneTics (IMGT) directory for the identification of IGHV-D-J and IGK/LV-J rearrangements and for computation of mutational load Lefranc et al, 2005; Pommie et al, 2004) . IGV sequences were considered M or UM using the canonical cut-off of 2% mismatch from germline IGV sequences (Damle et al, 1999; Hamblin et al, 1999) . In the case of IGHD gene determination, the IMGT/Junction analysis tool was used, following established IMGT criteria (Yousfi et al, 2004) .
For HCDR3-driven clustering, all in-frame immunoglobulin heavy-chain (IGH) rearrangements were first converted into amino acid (AA) sequences and then aligned according to the putative HCDR3 AA sequences by using the multiple sequence alignment software ClustalX (1.83) (Thompson et al, 1997) . For this purpose, the length of HCDR3 was calculated between codons 107 and 117 (IMGT numbering). Withdrawal of the usually conserved codons 105-106 (Honegger & Pluckthun, 2001) , although part of HCDR3 according to IMGT criteria Lefranc et al, 2005; Pommie et al, 2004) , was chosen to maximize differences among sequences.
Tightly clustering HCDR3 AA sequences were selected, visually inspected and further checked for similarity by aligning them again by means of ClustalX (1.83). Clusters identified as having similar/identical HCDR3 AA sequences were those characterized by a mean alignment score (MAS) equal or exceeding the value of 60/100. MAS was the mean value of all the pairwise alignment scores, as determined by ClustalX (1.83). Cluster nomenclature was according to Stamatopoulos et al (2007) and Murray et al (2008) . Clusters not included in this nomenclature system were assigned a number preceded by the alphabet letter N ('Novel'). In selected cases, IGHV gene sequences of M CLL belonging to homologous clusters were analysed for the frequency of specific AA changes, as previously described (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a) .
Immunophenotypic analyses
Detection of CD38, CD49d and ZAP-70 expression was as reported (Gattei et al, 2008; Rassenti et al, 2004 (Bomben et al, 2007; Crespo et al, 2003; Del Principe et al, 2006; Gattei et al, 2008; Orchard et al, 2004; Rassenti et al, 2004) .
Analysis of cytogenetic aberrations
Cytogenetic abnormalities involving chromosomes 11, 12, 13 and 17 were investigated by interphase fluorescent in situ hybridization (FISH) analysis. Probes used were: LSI-ATM for del11q22-q23, LSI-13 and LSI-D13S319 for del13q14, LSI-p53 for del17p13 and CEP12 for trisomy 12 (Vysis Inc, London, UK). FISH procedures were as reported previously (Del Principe et al, 2004 Del Poeta et al, 2005) . For each probe, at least 200 nuclei were examined.
Statistical analysis
All statistical analyses were performed using the R statistical package (http://www.r-project.org/). The end point for clinical correlations was time-to-treatment (TTT), defined as time from diagnosis to first treatment (event) or end of follow-up (censored observation). In the cohort utilized for TTT analyses (698 patients), treatment initiation was according to National Cancer Institute Working Group criteria (Cheson et al, 1996) . TTT was estimated using Kaplan-Meier plots and comparisons between groups were made by means of log-rank test. The Cox proportional hazard regression model was chosen to assess the 
Results
A total of 1426 in-frame IGHV-D-J rearrangements were sequenced in 1398 patients. In keeping with previous studies, double or triple in-frame rearrangements were found in 22 and 3 cases, respectively (Degan et al, 2004a; Stamatopoulos et al, 2007) . (Crespo et al, 2003; Damle et al, 1999; Degan et al, 2004a; Del Poeta et al, 2001; Dohner et al, 2000; Durig et al, 2002 Durig et al, , 2003 Gattei et al, 2008; Hamblin et al, 2002 Hamblin et al, , 1999 Hamblin et al, , 2000 Krober et al, 2002; Orchard et al, 2004; Rai et al, 1975; Bomben et al, 2007; Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a; Tschumper et al, 2008) .
Identification of CLL with homologous HCDR3
Three hundred and nineteen (22AE4%) sequences carried a homologous HCDR3 (Hom sequences) by HCDR3-driven clustering and were split into 69 different clusters, the majority of which (46/69) have not been previously reported (Table  SIV) Hom sequences with UM rearrangements occurred among IGHV1 and IGHV3 subgroups (P < 0AE0001), although more than half of the Hom sequences with M rearrangements belonged to IGHV3 subgroup (67/121; 55AE4%). Accordingly, the chance of belonging to a given cluster was significantly higher for IG rearrangements using IGHV1 subgroup genes compared to rearrangements employing other subgroups (P < 0AE0001; Table I ; Fig 1A) . Conversely, IG rearrangements using IGHV3 subgroup genes were significantly under-represented among Hom sequences (P < 0AE0001; Table I ; Fig 1A) .
Skewed usage of specific IGHV genes was observed by comparing Hom and Het sequences. IGHV1-69 (73/319; 22AE9%) and IGHV3-21 (33/319; 10AE3%) were the most frequently utilized genes by Hom sequences (Fig 1B) . Of note, IGHV3-21 was the only gene employed more frequently by Hom than by Het sequences (Fig 1B) , whereas IGHV3-23 (130 Het sequences/134 total sequences) and IGHV4-34 (99 Het sequences/128 total sequences) were preferentially employed by Het sequences (Fig 1B) .
Molecular features of clusters with homologous HCDR3
Thirty of 69 clusters included at least 3 sequences/clusters (range 3-32). These clusters indicated as confirmed clusters in agreement with previous studies (Murray et al, 2008; Stamatopoulos et al, 2007) , accounted for 241 sequences (16AE9%), 80 with M and 161 with UM IGHV genes (Table II and  Table SIV ). Fifteen of 30 confirmed clusters (150 sequences) were exclusively/mainly composed of UM sequences (UM/ M = 148/2; UM clusters), 14 clusters (59 sequences) were exclusively/mainly composed of M sequences (UM/M = 3/56; M clusters) and a single cluster (Cluster 2), represented by 32 sequences using IGHV3-21, included both UM and M sequences (UM/M = 10/22).
Within each confirmed cluster, identical IGHV genes were used in 22 clusters. In the remaining 8 clusters, a prevalent IGHV gene was found in 3 clusters (Clusters 3, 7 and 9) while in the other 5 clusters, IGHV genes often belonged to the same subgroup or clan (Table II) (Table II and Table SIV) .
Sixteen of 30 confirmed clusters (196 sequences) were common to other CLL datasets (common clusters; Table II  and Table SIV) (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a; Widhopf et al, 2008 Widhopf et al, , 2004 . With the only exception of Cluster 2 (IGHV3-21/ IGLV3-21), including both M and UM sequences (Bomben et al, 2007; Ghia et al, 2005; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2002 Tobin et al, , 2003 , the great majority of common clusters (12 of 15) were UM. UM clusters included: i) six clusters (Clusters 3, 5, 6, 7, 9 and 59) that exclusively/ mainly utilized IGHV1-69; ii) two clusters utilizing either IGHV1-2 alone (Cluster 28) or IGHV1-2 together with other IGHV1 genes, though not IGHV1-69 (Cluster 1); iii) two clusters utilizing IGHV4-39 either alone (Cluster 8, characterized by IGG-expressing cases) (Ghiotto et al, 2004; Messmer et al, 2004b; Stamatopoulos et al, 2007) or in association with other IGHV genes (Cluster 10); iv) two clusters (Clusters 109 and 26) utilizing exclusively/mainly genes from IGHV3 subgroup. The remaining three common clusters were M clusters utilizing either IGHV4-34 (Clusters 4 and 29, the former containing IGG-expressing cases) (Ghiotto et al, 2004; Messmer et al, 2004b; Stamatopoulos et al, 2007) or IGHV4-59 (Cluster 13; Table II ).
In addition to previously reported common clusters, we also identified 14 novel (Clusters N1-N14) confirmed clusters, accounting for 45 sequences (novel clusters). In contrast to common clusters, the majority of novel clusters (11/14) were M clusters (Table II) . The different distribution of UM and M clusters among common and novel clusters was statistically significant (P = 0AE0054). Of note, 8 of 11 novel M clusters expressed genes from the IGHV3 subgroup (IGHV3-30, 3 clusters; IGHV3-33, 1 cluster; IGHV3-48, 2 clusters; IGHV3-7, 1 cluster; IGHV3-72, 1 cluster), and 9 of 11 revealed restricted light chain usage (Table II and Table SIV) . Finally, out of the total 69 clusters, we identified 39 clusters (Table III) composed by pairs of sequences. These clusters were labelled as potential clusters in keeping with previous reports (Murray et al, 2008; Stamatopoulos et al, 2007) . Nineteen out of 39 potential clusters had the same IGHV-D-J configuration, while the remaining 20 clusters expressed either the same IGHV-D (2 clusters), IGHV-J (6 clusters), IGHV (3 clusters), IGHD-J (8 clusters) or IGHJ (1 cluster) genes (Table III) . As also observed for confirmed clusters, most of the potential clusters (32/39) were exclusively composed either by M (17/39) or UM (15/39) sequences. The same light chain was shared by 8 of 26 clusters for which data were available. Fourteen of 39 potential clusters displayed homology with CLL from other datasets or with single CLL cases that have been previously reported (Table III and Table SIV) (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a; Widhopf et al, 2008 Widhopf et al, , 2004 . The high number of confirmed clusters composed by sequences with a M IGHV gene status prompted us to investigate whether, in the context of these M clusters, CLL sequences shared AA changes (i.e. replacement of the same AA in the same position) also outside the HCDR3 region (Murray et al, 2008) . As shown in Fig S2, shared AA changes were found across the whole IGHV gene sequence in all but one (Cluster N11) of the 14 M clusters. Moreover, the vast majority of these shared AA changes were cluster-biased, since they occurred significantly more frequently in Hom sequences than in Het sequences expressing the same M IGHV gene (Table SV) .
Clinical features of CLL with homologous HCDR3
Among 698 patients with available TTT, 159 were Hom cases and 539 were Het cases. Although median TTT was found to be shorter in Hom than in Het cases (38 months vs. 70 months; P = 0AE0003; Fig S3A) , this difference was no longer true by comparing Hom and Het CLL in the context of the M or UM CLL subsets (Fig S3B) . This clearly indicates that TTT differences between Hom and Het cases have to be ascribed to the prevalence of UM cases among Hom CLL (Table I) . Time-to-treatment was then investigated by comparing Hom CLL belonging to the largest clusters (Clusters 1-8; Table II) (Table II and Table SIV ) (Tobin et al, 2004a; Stamatopoulos et al, 2007; Messmer et al, 2004b) . Sequences belonging to Cluster 1 were identified among 135 sequences carrying the same IGHV genes, which included sequences either not belonging to any cluster (92 sequences) or included in other clusters (13 sequences).
Time-to-treatment intervals were available for 12 cases included in Cluster 1. As shown in Fig 2A- C, the prognosis of these patients was poor either when compared with the whole series of UM/M cases (UM/M = 269/417) or to cases expressing the same IGHV genes and not belonging to Cluster 1 independently on their IGHV mutational status (UM/M = 23/20). Consistently, the presence of unfavourable prognosticators was significantly more frequent in cases belonging to Cluster 1 than in Het cases expressing the same IGHV genes (P = 0AE009; Fig 2D) .
Cluster 2. IGHV3-21 was rearranged in 58/1426 (4AE1%) sequences (UM/M = 18/40). Thirty-two (UM/M = 10/22) of 58 sequences (55AE0%) expressed the previously described stereotyped BCR characterized by an unusually short HCDR3 combined with IGLV3-21 and were included in Cluster 2 (Table II and Table SIV) (Bomben et al, 2007; Ghia et al, 2005; Tobin et al, 2002 Tobin et al, , 2003 . The remaining 26 IGHV3-21 sequences had longer and unrelated HCDR3, rarely associated (2/16 tested cases) with IGLV3-21 (Bomben et al, 2007; Ghia et al, 2005; Murray et al, 2008; Stamatopoulos et al, 2007) .
Information on TTT was available for 29 patients with IGHV3-21 CLL (15 Hom cases belonging to Cluster 2 and 14 Het cases). Despite the presence of 9/15 cases with M IGHV genes, TTT intervals of Hom cases were comparable with those of UM cases (Fig 3A) . Conversely, the clinical behaviour of the small cohort of IGHV3-21 Het cases (UM/M = 4/10) was closely dependent upon IGHV mutational status (Fig 3B) . The 10 M Het cases expressing IGHV3-21 had significantly longer TTT intervals compared with the 9 M Hom cases included in Stamatopoulos et al (2007) and Murray et al (2008) . Clusters not included in this nomenclature system are identified with numbers preceded by the alphabet letter N. *Number of cases in a given CLL cluster. Number of cases with mutated IGHV genes over cases with unmutated IGHV genes. àMAS was the mean value of all the pairwise alignment scores for all the sequences belonging to a specific cluster, as computed by ClustalX (1.83). §Similar to previously published clusters; references are reported in text and Table SIV .
-Publicly available non-CLL sequences potentially belonging to the same cluster; accession numbers are reported in Table SIV . **Publicly available CLL sequences potentially belonging to the same cluster; accession numbers are reported in Table SIV . Cluster nomenclature is according to Stamatopoulos et al (2007) and Murray et al (2008) . Clusters not included in this nomenclature system are identified with numbers preceded by the alphabet letter N. *Number of cases in a given CLL cluster. Number of cases with mutated IGHV genes over cases with unmutated IGHV genes. àMAS was the mean value of all the pairwise alignment scores for all the sequences belonging to a specific cluster, as computed by ClustalX (1.83). §Similar to previously published clusters; references are reported in text and Table SIV .
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-Publicly available CLL sequences potentially belonging to the same cluster; accession numbers are reported in Table SIV . **Publicly available non-CLL sequences potentially belonging to the same cluster; accession numbers are reported in Table SIV .
Cluster 1 (Fig 3C) . Consistently, IGHV3-21 Hom cases expressed unfavourable prognosticators more frequently than IGHV3-21 Het cases (P = 0AE002; Fig 3D) .
Discussion
Alignment analyses of 1426 functional in-frame IGHV-D-J rearrangements corresponding to a series of 1398 unselected CLL led to the identification of 69 different clusters accounting for 319 sequences (22AE4%). This approach enabled the identification of several clusters (46/69) not reported by previous studies (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a; Widhopf et al, 2008) . However, since the novel clusters turned out to have mostly two or three sequences per cluster, the overall percentage of Hom cases was comparable with other reports (Murray et al, 2008; Stamatopoulos et al, 2007) . It is unlikely that the identification of novel clusters may be ascribed to unwanted biases of this CLL series. In fact, our series did not show any significant difference in frequency of IGHV, IGHD and IGHJ gene usage compared with other published series (Degan et al, 2004a; Ghia et al, 2005; Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a; Widhopf et al, 2008) . The present study performed cluster analysis by purposely disregarding IGHV genes and considering HCDR3 sequences alone for alignment. Given that HCDR3 represents the most variable region of IGH chains and is known to be directly involved in binding to canonical antigens (Maccallum et al, 1996) , such a strategy appeared to be appropriate for identifying clusters potentially selected by similar/identical antigens. Conversely, in other studies, expression of the same IGHV gene was chosen as a prerequisite for cluster identification (Messmer et al, 2004b; Tobin et al, 2004a; Widhopf et al, 2008 Widhopf et al, , 2004 . A HCDR3-driven clustering similar to that employed in the present investigation was utilized in previous studies (Murray et al, 2008; Stamatopoulos et al, 2007) . At variance with these studies, we calculated HCDR3 length withdrawing the usually conserved codons 105-106 (Honegger & Pluckthun, 2001 ) to maximize differences among sequences and utilized the MAS value to identify homologous clusters (Thompson et al, 1997) . Some of the differences between this and previous studies could be at least in part the result of different approaches chosen for clustering.
Despite our choice of a strict HCDR3-driven clustering approach, 22/30 confirmed clusters carried identical IGHV genes or shared the expression of the same light chain either in all or in the majority of the analysed cases. Clusters expressing different IGHV genes displayed either a single prevalent IGHV gene (e.g. IGHV1-69 prevalence in Clusters 3, 8 and 9) or IGHV genes belonging to the same subgroup/clan (e.g. IGHV1 and IGHV7 subgroup genes in Cluster 1) (Murray et al, 2008; Stamatopoulos et al, 2007; Messmer et al, 2004b; Tobin et al, 2004a; Widhopf et al, 2008 Widhopf et al, , 2004 Vargas-Madrazo et al, 1997) .
Sixteen of 30 confirmed clusters were common to other CLL datasets (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a) . With the exclusion of Cluster 2 (the IGHV3-21/IGLV3-21 cluster) (Bomben et al, 2007; Ghia et al, 2008 Ghia et al, , 2005 Tobin et al, 2002 Tobin et al, , 2003 , which was the sole cluster accounting for both UM and M cases, and of 3 M clusters utilizing IGHV4-34 and IGHV4-59 (Ghiotto et al, 2004; Murray et al, 2008; Stamatopoulos et al, 2007) , the vast majority of common clusters comprised UM cases (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a) . These UM clusters included cases that have been recognized as expressing both autoreactive and polyreactive BCR, allegedly deriving from the B cell compartment devoted to the production of natural antibodies (Borche et al, 1990; Dighiero et al, 1983; Herve et al, 2005; Lanemo Myhrinder et al, 2008; Martin et al, 1992; Sthoeger et al, 1989; Widhopf et al, 2008) . Autoreactivity has been also hypothesized for the M cluster utilizing IGHV4-34 (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007) , although occurring via conserved residues located outside the conventional HCDR antigen-binding sites (Murray et al, 2008; Silverman & Goodyear, 2002 .
The remaining 14/30 confirmed clusters accounting for 45 sequences were not previously reported. Although also in our series the chance of carrying a stereotyped BCR was significantly higher for UM CLL (Messmer et al, 2004b) , the majority of these novel clusters (11/14) unexpectedly expressed stereotyped BCR with M IGHV rearrangements, often involving (8/11) IGHV3 subgroup genes. Of note, recurrent AA changes were demonstrated to occur across the entire IGHV region in all novel M clusters. These mutations were significantly underrepresented in CLL expressing the same IGHV genes but not included in clusters, and therefore were considered clusterbiased, as previously reported (Murray et al, 2008) .
Lack of detection of these novel clusters by previous studies, including those dealing with comparably wide datasets (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a) , raises the possibility that the frequency of these clusters might be subjected to a geographical bias. In this regard, a significantly skewed representation of another IGHV3 gene, i.e. IGHV3-21, has been well documented in different European and non-European countries (Ghia et al, , 2005 Tobin et al, 2002 Tobin et al, , 2003 , and even in different regions from the same country (Bomben et al, 2007) . Similarly, two clusters of our series expressing IGHV3-30 (Cluster N8) and IGHV3-33 (Cluster N10) were shown to have quasi-identical HCDR3 sequences when compared with two cases and to a single case reported elsewhere as belonging to an Italian series (Murray et al, 2008; Stamatopoulos et al, 2007) . Another novel M cluster (Cluster N13) expressed IGHV3-72 in association with highly homologous HCDR3 and IGKV4-1. Two additional IGHV3-72-expressing potential M clusters (Clusters 68 and N30), one also reported elsewhere (Murray et al, 2008) were associated with IGKV1-16. Of note, frequent usage of IGHV3-72 has been reported in highly stable and
The Authors indolent CLL from an Italian cohort of patients not included in the present study (Capello et al, 2004 (Capello et al, , 2006 Guarini et al, 2003) .
The finding of several novel clusters involving IGHV3 subgroup genes may appear surprising, given the property of genes from this subgroup to bind superantigens, i.e. specific unconventional antigens (e.g. microbial proteins) capable of reacting with IG through residues located outside the conventional HCDR antigen-binding sites (Sasso et al, 1989; Silverman & Goodyear, 2002 Seppala et al, 1990; Domiati-Saad & Lipsky, 1998) . Given that CLL in clusters show clear evidence by expressing IG rearrangements with homologous HCDR3 for a selection driven by conventional antigens, it is conceivable that at least certain genes of the IGHV3 subgroup may bind antigens via canonical pathways of HCDR-mediated recognition Silverman & Goodyear, 2002 .
From a clinical standpoint, the presence of stereotyped BCR was not a feature with prognostic significance in our series. In fact, although TTT was significantly shorter for Hom CLL compared with Het CLL, this was ascribed to the presence of a larger number of UM cases among Hom CLL, as described here and previously (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a) . Nevertheless, by comparing the clinical features of Hom and Het cases in the context of specific stereotyped BCR, novel clinical features emerged.
Cases belonging to Cluster 1 expressed IGHV1 subgroup genes other than IGHV1-69 and displayed highly homologous HCDR3 sequences in association with a common light chain 
Cluster1
Cluster1 Het (Messmer et al, 2004b; Murray et al, 2008; Stamatopoulos et al, 2007; Tobin et al, 2004a) . Although Cluster 1 CLL always had an UM IGHV status, TTT intervals of these patients were shorter when compared with the whole series of UM/M cases and to UM cases expressing the same IGHV genes but not included in clusters. A similar clinical behaviour was also suggested by the sole previous study identifying the same cluster (Stamatopoulos et al, 2007) . Results from this and the present study, concordantly indicate that Cluster 1 CLL has the worst prognosis in CLL.
Here, we provide evidence that Hom IGHV3-21 CLL have shorter TTT when compared with: (i) all M CLL; (ii) M CLL expressing IGHV3-21 but not included in Cluster 2. Consistently, this latter group of patients had significantly longer TTT intervals compared with a small subgroup of CLL included in Cluster 2 that expressed a M IG rearrangement. The distribution of several prognosticators was in keeping with this clinical behaviour. The prognostic relevance of stereotyped BCR among IGHV3-21 CLL is presently still unclear (Bomben et al, 2007; Ghia et al, 2005; Thorselius et al, 2006) . In particular, whilst no differences were found by comparing the clinical courses of patients affected by IGHV3-21 CLL with Hom versus Het HCDR3 (Thorselius et al, 2006) , the molecular basis for a more aggressive clinical outcome of Hom versus Het IGHV3-21 CLL has been suggested by gene expression profiling and immunophenotypic analyses (Bomben et al, 2007) . These discrepancies can be explained by the different clinical end-points (TTT vs. overall survival) employed in the present versus previous studies (Thorselius et al, 2006) . Further studies combining the effort of several institutions and specifically focusing on IGHV3-21 CLL patients are needed to definitively solve this issue. The notion that patients affected by Hom IGHV3-21 CLL experience a more progressive disease may have important implications, given the proposal of using IGHV3-21 expression to drive clinical decision in prospective trials et al, 2007). Finally, we were unable to reproduce the different clinical outcome previously suggested for IGHV1-69 CLL belonging to different clusters of stereotyped BCR (e.g. Clusters 3 and 5) (Stamatopoulos et al, 2007) . In our series, clinical courses of Hom versus Het CLL expressing IGHV1-69 were similar and mostly dependent upon IGHV mutational status, as also reported elsewhere (Panovska-Stavridis et al, 2007) .
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